'Merck Nears $6bn Biotech Deal To Boost Cancer Drug Pipeline' - FT

Merck is reportedly nearing a $6 billion deal to acquire a biotechnology company, aimed at enhancing its cancer drug pipeline. This strategic move is expected to strengthen Merck's position in the oncology market. The deal reflects Merck's ongoing commitment to expanding its portfolio in the competitive biotech landscape.